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ac.ukParasite immunologists have contributed signiﬁcantly to our understanding of the human immune sys-
tem, to the extent that live parasites are being tested as investigational medicinal products (IMPs) and
their secretions are being analysed for potentially novel and effective immune regulatory molecules
(IRMs). This article expresses an opinion on the current status of research, and suggests that parasite
immunologists and the pharmaceutical industry combine to source non-immunogenic IRMs from para-
sites selected for their immune modulatory potential. The article also suggests that parasite immunolo-
gists should be perhaps more rigorous in their choice of infection and disease models in rodents.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY license.1. Introduction and activity in a range of disease models. ES 62 is a ‘‘haptenated’’The scientiﬁc literature on the immunobiology of host-parasite
relationships is replete with examples of parasite molecules which
have perhaps been optimistically nominated for their potential to
be developed as therapeutics, to treat immunological diseases such
as allergy and autoimmunity.
Parasite-derived molecules have achieved this exalted status
possibly because of the over-enthusiasm of parasitologists for their
subject, supported by the argument that endoparasites in particu-
lar have evolved to moderate the immune system, allowing them
to survive in what is essentially a hostile environment.
It seems that parasites have adapted to engage immune regula-
tory networks, a facet of parasitology that could represent an
attractive area of research for the pharmaceutical industry. The
expansion of regulatory leucocyte populations by candidate mole-
cules from parasites, for example, could be exploited to treat
immunological diseases (allergy and autoimmunity) caused by
many types of immune hypersensitivity which exist.
This strategy would need to be balanced against the involve-
ment of regulatory leucocytes in tumour progression (Khan et al.,
2010).
The list of candidate parasite molecules is relatively long, and
rather than reiterate what has already been published, the reader
is referred to Table 1 of a review by Harnett and Harnett (2010),
a table containing a panoply of candidate molecules.
The ﬁlarial-derived ES 62 seems to lead the race for the devel-
opment of parasite-derived therapeutics, given its characterisationPublished by Elsevier Ltd.
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Open acprotein, and the immune-modulatory activity of the complex
would appear to reside with the phosphorylcholine (PC) which is
chemically linked to the ES 62 (kDa) protein. As ES62 is immuno-
genic, researchers are exploring immune-modulatory chemical
analogues of phosphorylcholine, which may not be immunogenic,
as non-haptenated small molecules. Nevertheless, a signiﬁcant
problem associated with many of the candidates listed in the Har-
netts’ review is the potential immunogenicity of many of the mol-
ecules listed. This property immediately renders almost all
candidates listed inappropriate for pharmaceutical development.2. Don’t take me alive?
Given the cost of researching and developing new chemical
entities for the treatment of immune diseases, and the problems
inherent to existing candidates, it may paradoxically and counter
– intuitively be more efﬁcient to administer the immune-modula-
tory parasitic organisms themselves, at least in the short term.
This approach presents its own problems, as parasitic organ-
isms theoretically offer no biological beneﬁt to their hosts, and
can be pathogenic.
Regardless, two candidate ‘‘therapeutic parasite products’’ have
emerged recently, Trichuris suis ova or TSO, and a hookworm
which infects humans, Necator americanus (Pritchard et al., 2012;
Summers et al., 2003, 2005, 2010).
A breakthrough was made when parasites were ‘‘manufac-
tured’’ in ways which rendered the subsequent investigational
medicinal product or IMP acceptable to regulatory agencies. This
has meant that a number of clinical trials have been conducted
with each product life cycle regulated according to rigid pharma-
ceutical standards.cess under CC BY license.
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have been extensively published, (Bager et al., 2010; Pritchard
et al., 2012; Summers et al., 2003, 2005, 2010); it is reasonable
to state that TSO is best supported in terms of the clinical data
available (Fleming et al., 2011). Nevertheless, some concerns have
been expressed over the use of TSO, a zoonosis in humans (Kradin
et al., 2006).
Trial data for hookworm are limited so far to short-term
(12 week) safety studies, where infection with 10 worms was well
tolerated, and induced an immunological phenotype associated
with natural (immune-regulatory?) infection. A new trial
(WIRMS-1) is underway in multiple sclerosis, where 25 larvae will
be resident for a possibly therapeutic 48 week period.
3. Future research proposals
While there is little doubt that parasite immunologists have
contributed signiﬁcantly to our understanding of the immune sys-
tem, and parasites remain to me an attractive source of potential
pharmaceutical products, important questions remain.
 What is the most efﬁcient way to use the knowledge gained to
date in order to beneﬁt patients suffering from diseases which
are still poorly served by conventional medicines?
 Does live therapeutic infection represent the way forward, in
humans for the treatment of human diseases?
 Should drug-discovery programmes, sourcing molecules from
parasite secretions, run in parallel?
 Is a continuation of research in murine models really necessary?
Here are some thoughts on these questions.
4. Living therapeutics
In the short term, live worm infection has distinct advantages in
the absence of pathogenicity, provided efﬁcacy can be shown con-
sistently in clinical trial.
The immune-modulatory product is cheap, easy to deliver and
could be long – acting in the case of hookworm infection. The prod-
uct is here now, but awaits proof of efﬁcacy.
5. Parasite products as targeted therapeutics
Because parasites are immunogenic, yet long-lived in an immu-
nologically active environment, it is likely that the molecules
responsible for naturally delivered immune regulation are non-
immunogenic, otherwise their effect would be neutralised. There-
fore, if live worm infection is efﬁcacious in moderating disease,
the organisms responsible for efﬁcacy should be investigated for
the presence of non-immunogenic and potentially novel immune-
modulatory compounds.
However, from past experience of working within and with
what is essentially a risk-averse pharmaceutical industry, I expect
a reluctance on their behalf to tread this unconventional discovery
path. Although many successful immune modulatory compounds
derive from natural products (cyclosporin, rapamycin), albeit
through serendipitous discovery, the industry seems reluctant to
invest in a search for rationally – sourced natural immune-modu-
latory products at this time. Drawing from personal experience, the
search for products from parasites has been termed a ﬁshing exer-
cise, and primeval, by critics within the industry. I would argue that
the ﬁshing is at least taking place in an immunologically appropri-
ate scientiﬁc environment (Pritchard, 2005), and it is clear that the
sources of potential new drugs have evolved to moderate the im-
mune system.In defence of the pharmaceutical industry, one reasonable rea-
son for their stance would be the argument that the parasite mol-
ecules responsible will turn out to be already known to science,
thus negating any opportunity to claim intellectual property. How-
ever, this is a stance that is unlikely to help patients in need of
treatment today.6. Using murine systems to discover drug targets
I would suggest that the pharmaceutical industry at least takes
a look at carefully considered host-parasite relationships, to aid the
discovery of new and/or relevant biological targets for immune
regulation and, in turn, targeted therapeutics. For example, it
would help them to know which molecular mechanisms are used
by worms to expand regulatory lymphocyte populations, for the
reasons outlined in the introduction. The study by Grainger and
his colleagues (2010), begins to explore this aspect of parasite
immunology. Here, they propose that a putative ligand for the
TGF b receptor exists in nematode secretions; ligation expands reg-
ulatory populations, a signiﬁcant ﬁnding. However, despite the
obvious merits of this work, the paper also serves to support and
reinforce my argument that a lack of molecular immunogenicity
is key to drug discovery. In looking to isolate immune-modulatory
molecules, the authors chose a concentration method that selects
proteins of mass greater than 10 kDa. The secretions in question
are already known to contain low-mass, proteinase resistant T cell
modulators (Telford et al., 1998). Furthermore, if ‘‘immunogenic-
ity’’ in the form of immune-receptor ligation is necessary for the
desired therapeutic effect, then this must be achieved by a non-
immunogenic process. The TGF b ligands they seek are likely to
be immunogenic, and neutralised once introduced to the body as
a therapeutic. This takes us back full circle to ES-62, and non-
immunogenic chemical analogues thereof.7. Summary
In closing, it would appear that parasite immunologists have set
the scene for a novel drug discovery programme. However, now
may be a time for reﬂection, prior to moving forward.
For example, if parasite immunologists wish to continue justify-
ing their research by arguing that an increase in the understanding
of a particular host-parasite relationship will lead to the discovery
of novel drugs for the treatment of immunological diseases, I
would strongly advocate a moratorium on many of the models
used by theMus musculus-entric, on the grounds that some models
do not remotely conform to the natural balance between host and
parasite. Is it not time for some of these models to be discarded, for
scientiﬁc and moral reasons?
Furthermore, many of the observations made using molecules
from murine parasites in murine systems have been replicated in
tissue culture using cells from human donors. Another reason per-
haps to reduce the use of rodents.
To confound the issue further, many of the human disease mod-
els established in mice are considered by many, in personal com-
munication, to be equally inappropriate. To then over-burden an
inappropriate disease model with parasitic infection is somewhat
perverse.
Again, it might be ultimately more valuable to conduct albeit
more challenging studies in human systems as opposed to over-
dosing rodents with excessive worm infections.
I also think that it would be more sensible for new studies to
search for non-immunogenic immune modulators from the
outset. The current ﬁxation on proteins and, if you claim ﬁnding
immune-modulatory proteins will be difﬁcult, the transcriptome,
perhaps results in the baby being thrown out with the bathwater.
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